双能CT评估聚乙二醇重组尿酸酶联合甲氨蝶呤联合治疗中单钠尿酸盐快速耗竭与骨侵蚀重塑
本报告呈现MIRROR开放标签试验中接受聚乙二醇重组尿酸酶联合甲氨蝶呤联合治疗患者的双能CT表现。2例患者系列双能CT显示,治疗期间单钠尿酸盐体积分别下降99%和58%,并可见骨侵蚀重塑,双能CT可检测亚临床单钠尿酸盐沉积。
要点
- 患者1完成52周联合治疗,单钠尿酸盐体积下降99%,骨侵蚀重塑明显。
- 患者2治疗10周因降尿酸反应丧失停药,单钠尿酸盐体积下降58%,骨侵蚀重塑明显。
- 双能CT检测到的单钠尿酸盐受累关节数远多于体检发现的痛风石受累关节数。
核心结论
- 双能CT可检测亚临床单钠尿酸盐沉积并量化其随时间的变化。
- 聚乙二醇重组尿酸酶联合甲氨蝶呤联合治疗期间出现快速痛风石溶解和骨侵蚀重塑。
研究设计与样本
- MIRROR开放标签试验中接受聚乙二醇重组尿酸酶(8 mg每两周静脉输注)联合口服甲氨蝶呤(15 mg/周)联合治疗的患者,进行系列双能CT扫描。
- 分析双侧手/腕、肘、足/踝和膝图像,采用默认后处理设置,量化单钠尿酸盐体积并识别和评估骨侵蚀重塑(尺寸减小、硬化、新骨形成)。
- 比较双能CT与体格检查发现。
主要发现
- 患者1(44岁男性)完成52周联合治疗(26次输注),基线体检发现4个痛风石受累关节,双能CT识别73个单钠尿酸盐受累关节(总单钠尿酸盐体积128.76 cm3);治疗结束时无临床受累关节,4个关节有双能CT检测到的单钠尿酸盐沉积,单钠尿酸盐体积下降99%,骨侵蚀重塑明显。
- 患者2(51岁男性)接受10周治疗(5次输注),因降尿酸反应丧失停药,基线体检发现7个痛风石受累关节,双能CT识别55个单钠尿酸盐受累关节(总单钠尿酸盐体积59.20 cm3);治疗结束时5个临床受累关节,42个关节有双能CT检测到的单钠尿酸盐沉积,单钠尿酸盐体积下降58%,骨侵蚀重塑明显。
- 双能CT检测到的单钠尿酸盐受累关节数多于体格检查发现的痛风石受累关节数(患者1基线:73 vs 4;患者2基线:55 vs 7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pegloticase rapidly lowers serum urate in uncontrolled/refractory gout patients, with ≥1 tophus resolution in 70% of pegloticase responders and 28% of non-responders. Dual-energy computed tomography (DECT) non-invasively detects MSU deposition, including subclinical deposition, quantifies MSU volumes and depicts bone erosions. This report presents DECT findings in MIRROR open-label trial participants receiving pegloticase+MTX co-therapy. METHODS: Serial DECT scans were obtained during pegloticase (8 mg biweekly infusions)+oral MTX (15 mg/week) co-therapy. Bilateral hand/wrist, elbow, foot/ankle and knee images were analysed with default post-processing settings. MSU volumes were quantified and bone erosions were identified and evaluated for remodelling (decreased size, sclerosis, new bone formation). DECT and physical examination findings were compared. RESULTS: 2 patients underwent serial DECT. Patient 1 (44-year-old male) completed 52 weeks of pegloticase+MTX co-therapy (26 infusions). Baseline examination detected 4 tophus-affected joints while DECT identified 73 MSU-affected joints (total MSU volume: 128.76 cm3). At end-of-treatment, there were no clinically-affected joints and 4 joints with DECT-detected MSU deposition. MSU volume decreased by 99% and bone erosion remodelling was evident. Patient 2 (51-year-old male) had 10 weeks of therapy (5 infusions), discontinuing because of urate-lowering response loss. Baseline examination detected 7 tophus-affected joints while DECT identified 55 MSU-affected joints (total MSU volume: 59.20 cm3). At end-of-treatment, there were 5 clinically affected joints and 42 joints with DECT-detected MSU deposition. MSU volume decreased by 58% and bone erosion remodelling was evident. CONCLUSION: DECT detected subclinical MSU deposition and quantified changes over time. Rapid tophus resolution and bone erosion remodelling occurred during pegloticase+MTX co-therapy. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT03635957.
引用
- Dalbeth N, Becce F, Botson JK, et al. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology (Oxford). 2022. PMID: 35293984. doi:10.1093/rheumatology/keac173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。